Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the launch of a new disease awareness campaign titled “We’ll Get There Soon” on FCS Awareness Day. The initiative aims to raise awareness about Familial Chylomicronemia Syndrome (FCS), a rare and severe condition characterized by persistently high triglyceride levels that can lead to serious health issues, including acute pancreatitis.
The campaign includes a dedicated website, www.LowerTriglycerides.com, along with social media pages on Instagram and Facebook, providing a platform for individuals affected by FCS to share their stories. A major goal of the campaign is to educate the community about expert guidelines recommending that triglyceride levels be kept below 500 mg/dL to reduce the risk of acute pancreatitis.
To kick off the campaign, Arrowhead hosted an event at its Pasadena headquarters, featuring special guests Julie Klueckman and her husband Gary, who shared their experiences with FCS. Julie’s journey highlights the difficulties faced by those living with the condition, including multiple misdiagnoses, prolonged hospital stays, a lack of effective medications, and the necessity of adhering to a strict low-fat diet of no more than 20 grams per day—equivalent to less than three tablespoons of peanut butter.
“My journey to diagnosis was incredibly challenging, taking a decade of research and advocacy to finally present my case to my doctor,” Julie shared. Despite her extensive medical history, including numerous hospitalizations and surgeries, she remains hopeful for the future of FCS patients. Julie is actively collaborating with the Arrowhead team to provide patient insights to enhance support for those affected by FCS, expressing her belief that “Hope is on the horizon.”
“We are honored to play a part in amplifying the voices of those impacted by FCS and bringing them hope. Julie’s story reminds us of our mission and reinforces Arrowhead’s core value of prioritizing patients and improving lives,” stated Alexendra Roeser, Director of Patient Advocacy at Arrowhead.
